Melanoma can be treated by interleukin-9 protein

US researchers found through research involving recombinant dog proteins that a protein has the efficacy of treating the skin cancer melanoma. This protein can be synthesized by the human body, so it is expected to develop new treatment to promote the body to fight against melanoma on this basis.

Melanoma is a malignant skin cancer, and the mortality rate is high. The researchers from Harvard University School of Medicine and other institutions conducted research on some melanoma patients with tissue samples and found that compared with normal levels, the patient code number for the interleukin-9 protein content is much lower or even missing.

The researchers also explored the effect of this protein on melanoma through animal experiments, and the results showed that if the mice injected with the inhibitory effect of interleukin-9 substances, the melanoma they suffer will grow rapidly, which is similar to human patients who have this protein in vivo.

However, if mice were injected with substances that promote an increase in their interleukin-9 levels, the rate at which they develop melanoma will decrease. This suggests that interleukin-9 is a protein that inhibits melanoma.

Interleukin-9 can achieve self-synthesis in the human and experimental mice, and we knew that it is a signal molecule which can mobilize the immune system in the past. The researchers suggested that in the future treatment of melanoma patients, it is suggested to promote the synthesis of more human interleukin-9 to mobilize the power of the immune system itself to inhibit tumor growth. Cusabio provides you with high-quality recombinant proteins such as recombinant Nrg2 at good prices.